Brief: Hansa Biopharma Q4 Operating Loss Narrows To SEK 144.7 Mln
02/02/2023 07:10
Feb 2 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA YEAR-END REPORT JANUARY-DECEMBER 2022
* TOTAL Q4 REVENUE OF SEK 31M
* Q4 OPERATING LOSS SEK 144.7 MILLION VERSUS LOSS SEK 162.8
MILLION YEAR AGO
Source text for Eikon: ID:nWkr4DNsVT
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS